Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy

被引：32
|
作者：
Jain, Preetesh [1 ]
Nastoupil, Loretta [1 ]
Westin, Jason [1 ]
Lee, Hun Ju [1 ]
Navsaria, Lucy [1 ]
Steiner, Raphael E. [1 ]
Ahmed, Sairah [1 ]
Moghrabi, Omar [1 ]
Oriabure, Onyeka [1 ]
Chen, Wendy [1 ]
Badillo, Maria [1 ]
Flowers, Christopher R. [1 ]
Wang, Michael L. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2021年 / 192卷 / 02期
关键词：
Mantle cell lymphoma (MCL); ibrutinib; brexucabtagene autoleucel; BTK inhibitor; venetoclax; chimeric antigen receptor therapy; non-Hodgkin lymphoma;
D O I：
10.1111/bjh.17197
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E38 / E42
页数：5
相关论文
共 50 条
  • [21] Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma: Real World Experience from the US Lymphoma CAR T Consortium
    Wang, Yucai
    Jain, Preetesh
    Locke, Frederick L.
    Munoz, Javier
    Maurer, Matthew J.
    Beitinjaneh, Amer
    Frank, Matthew J.
    Dahiya, Saurabh
    McGuirk, Joseph P.
    Jacobs, Miriam T.
    Goy, Andre H.
    Vose, Julie M.
    Hill, Brian T.
    Oluwole, Olalekan O.
    Deol, Abhinav
    Shah, Bijal D.
    Paludo, Jonas
    Wang, Trent
    Lekakis, Lazaros J.
    Miklos, David B.
    Rapoport, Aaron P.
    Ghobadi, Armin
    Neelapu, Sattva S.
    Lin, Yi
    Wang, Michael
    Jain, Michael D.
    BLOOD, 2021, 138
  • [22] Brexucabtagene autoleucel in relapsed or refractory mantle cell lymphoma, intention-to-treat use in the DESCAR-T registry
    Herbaux, Charles
    Bret, Caroline
    Bachy, Emmanuel
    Bories, Pierre
    Di Blasi, Roberta
    Cuffel, Alexis
    Gastinne, Thomas
    Lamy, Thierry
    Roussel, Mikael
    Bouabdallah, Krimo
    Beauvais, David
    Cartron, Guillaume
    Bay, Jacques-Olivier
    Blaise, Didier
    Rubio, Marie-Therese
    Mohty, Mohamad
    Le Bras, Fabien
    Casasnovas, Olivier
    Guy, Julien
    Guidez, Stephanie
    Llorente, Cristina Castilla
    Hermine, Olivier
    La Rochelle, Laurianne Drieu
    Carras, Sylvain
    Guffroy, Blandine
    Caillat-Zucman, Sophie
    Houot, Roch
    Le Gouill, Steven
    HAEMATOLOGICA, 2024, 109 (11) : 3745 - 3750
  • [23] Efficacy and safety of brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system involvement
    Lionel, Anath C.
    Gurumurthi, Ashwath
    Fetooh, Ahmed
    Eldaya, Rami
    Ahmed, Sairah
    Iyer, Swaminathan P.
    Nastoupil, Loretta J.
    Westin, Jason
    Nair, Ranjit
    Fayad, Luis
    Malpica, Luis
    Tummala, Sudhakar
    Flowers, Christopher
    Neelapu, Sattva S.
    Wang, Michael L.
    Jain, Preetesh
    LEUKEMIA & LYMPHOMA, 2024, 65 (05) : 669 - 673
  • [24] Uncommon Viral Infections in Patients Treated With CAR-T Cell Therapy: Concurrent Adenovirus and BK Virus Infection in a Mantle Cell Lymphoma Patient Within 30 Days After Receiving Brexucabtagene Autoleucel
    Tregubenko, Polina
    Abdelhakim, Haitham
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S442 - S443
  • [25] Brexucabtagene Autoleucel for Relapsed/ Refractory Mantle Cell Lymphoma: Real-World Experience From the US Lymphoma CAR T Consortium
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (02) : 16 - 18
  • [26] Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium
    Wang, Yucai
    Jain, Preetesh
    Locke, Frederick L.
    Maurer, Matthew J.
    Frank, Matthew J.
    Munoz, Javier L.
    Dahiya, Saurabh
    Beitinjaneh, Amer M.
    Jacobs, Miriam T.
    Mcguirk, Joseph P.
    Vose, Julie M.
    Goy, Andre
    Andreadis, Charalambos
    Hill, Brian T.
    Dorritie, Kathleen A.
    Oluwole, Olalekan O.
    Deol, Abhinav
    Paludo, Jonas
    Shah, Bijal
    Wang, Trent
    Banerjee, Rahul
    Miklos, David B.
    Rapoport, Aaron P.
    Lekakis, Lazaros
    Ghobadi, Armin
    Neelapu, Sattva S.
    Lin, Yi
    Wang, Michael L.
    Jain, Michael D.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (14) : 2594 - +
  • [27] Cladribine and Cyclophosphamide Lymphodepletion Prior to Brexucabtagene Autoleucel in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia and Mantle Cell Lymphoma
    Ionescu, Filip
    Faramand, Rawan
    Bailey, Hanna
    Bachmeier, Christina A.
    DiMaggio, Elizabeth
    Mohammed, Turab
    Isenalumhe, Leidy Lismeris
    Locke, Frederick L.
    Jain, Michael D.
    Shah, Bijal D.
    BLOOD, 2023, 142
  • [28] The CAR-Hematotox Score Identifies Patients at High Risk for Hematological Toxicity, Infections and Poor Clinical Outcomes Following Brexucabtagene Autoleucel in Relapsed/Refractory Mantle Cell Lymphoma
    Rejeski, Kai
    Wang, Yucai
    Albanyan, Omar
    Munoz, Javier L.
    Sesques, Pierre
    Iacoboni, Gloria
    Corral, Lucia Lopez
    Mohty, Razan
    Dreyling, Martin
    Locke, Frederick L.
    Barba, Pere
    Bachy, Emmanuel
    Lin, Yi
    Subklewe, Marion
    Jain, Michael D.
    BLOOD, 2022, 140
  • [29] COST-EFFECTIVENESS ANALYSIS OF AXICABTAGENE CILOLEUCEL, BREXUCABTAGENE AUTOLEUCEL, AND STANDARD OF CARE FOR TREATMENT OF RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA
    Ghanem, B.
    Brown, L.
    Seoane-Vazquez, E.
    VALUE IN HEALTH, 2022, 25 (07) : S375 - S375
  • [30] Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: A real-world intention-to-treat analysis
    OReilly, Maeve A.
    Wilson, William
    Burns, David
    Kuhnl, Andrea
    Seymour, Frances
    Uttenthal, Ben
    Besley, Caroline
    Alajangi, Rajesh
    Creasey, Thomas
    Paneesha, Shankara
    Elliot, Johnathon
    Arias, Carlos Gonzalez
    Iyengar, Sunil
    Wilson, Matthew R.
    Delaney, Alison
    Rubio, Lourdes
    Lambert, Jonathan
    Begg, Khalil
    Boyle, Stephen
    Cheok, Kathleen P. L.
    Collins, Graham P.
    Roddie, Claire
    Johnson, Rod
    Sanderson, Robin
    HEMASPHERE, 2024, 8 (06):
12345